drugset
Drugs / Novel Oral Polio Vaccine Type 3
last change Feb 2023 re-read 3 minutes ago

Novel Oral Polio Vaccine Type 3

also known as nOPV3

Vaccine

Developed for
poliomyelitis
Investigated by
Bill and Melinda Gates Foundation · Centers for Disease Control and Prevention · PATH · The Emmes Company, LLC · Viroclinics Biosciences B.V.

Trials 1

today NCT04529538 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04529538 Mar 2021 → Feb 2023 poliomyelitis PATH Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Novel Oral Polio Vaccine Type 3 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04529538 ↗
Known as nOPV3 “Novel Oral Polio Vaccine Type 3 (nOPV3)” NCT04529538 ↗
Modality Vaccine “novel oral polio vaccines” NCT04529538 ↗
Route Oral “Novel Oral Polio Vaccine Type 3 (nOPV3)” NCT04529538 ↗